
    
      This is a phase II pilot study to evaluate the efficacy and safety of osimertinib with
      bevacizumab for LM from EGFRm NSCLC patients. ALL patients were treated with Osimertinib 80mg
      oral daily and bevacizumab 7.5mg/kg intravenous every 3 weeks. Study therapy continued until
      disease progression, unacceptable adverse event, or withdrawal of consent.
    
  